Puterizumab
Phase 2Monoclonal antibody
Puterizumab is one of 55 small molecule programs targeting Metastasis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
62 competitors in Metastasis
#DrugCompanyPhaseTrials
1Gemzar
Johnson & JohnsonApproved
Camptosar
PfizerApproved
Femara
NovartisApproved
Norvir
AbbVieApproved
Neoral
NovartisApproved
Tukysa
PfizerApproved
Lynparza
AstraZenecaApproved
Taxol
TevaApproved
Trexall
Jazz PharmaceuticalsApproved
Verzenio
Eli LillyApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Puterizumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 2[1]
- Company
- SSir Run Run Shaw Hospital